2,464 material Form 8-K filings that 2,079 companies we cover made with the SEC in November 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 1,081 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Savers Value Village hosted an Innovation Day on November 10, 2026, showing its ThriftIQ pricing platform and the Autotagger and Image Capture labor-efficiency technologies, and outlining a three-year plan. The company expects revenue growth and Adjusted EBITDA margin expansion of 50 to 100 basis points per year, with a high-teens margin target and net leverage under 2x by the end of 2027. The filing's figures are forward-looking targets, and the company says the non-GAAP measures are not reconciled to GAAP.
ThriftIQ is live in 108 stores and has priced over 40 million items; the company says these stores show faster gross profit growth.
Targets a high-teens Adjusted EBITDA margin in the next three years, with 50 to 100 basis points of annual expansion.
Plans about 25 new store openings annually and net leverage ratio under 2x by the end of 2027.
Q3 2026 net sales rose 8.5% to $463 million and comparable store sales increased 4.2%.
Legacy Housing Corp's board appointed Darren McCallon as chief financial officer effective November 9, 2026, replacing Jon Langbert, who resumed his retirement on November 6, 2026. The filing says the company and Mr. McCallon expect to enter into an employment agreement, and it describes his background in financial reporting, capital planning and M&A. A CFO change is a significant leadership transition that shareholders may watch closely, but the filing contains no financial results or guidance.
Darren McCallon, age 55, appointed CFO by the board on November 6, 2026, effective November 9, 2026.
He succeeds Jon Langbert, who resumed his retirement on November 6, 2026.
Since 2023 he has been CFO of Fortune Insurance; previously CFO of 4WEB Medical from 2014 to 2023.
An employment agreement with the company is expected following his appointment; no terms are disclosed in the filing.
FS Bancorp said CFO Phillip D. Whittington will transition to Director of Accounting Operations and External Reporting, and will remain CFO until a successor is identified, expected by March 31, 2027. The company said the move was not the result of any disagreement and has started a formal internal and external search for a new CFO.
Phillip D. Whittington moves from Chief Financial Officer to Director of Accounting Operations and External Reporting.
Whittington stays CFO until a successor is identified, which is expected by March 31, 2027.
The company said the transition did not result from any disagreement with the Company or the Bank.
A formal internal and external search for a new CFO has been initiated.
Citizens & Northern Corporation posted an investor presentation to its website on November 10, 2026, with data as of or for the period ended September 30, 2026, and furnished it under Regulation FD. The deck includes a leadership update: CEO J. Bradley Scovill's retirement is planned for spring 2027 and a CEO search is in progress, and Chair Terry Lehman plans to step down as Chair in April 2027 while remaining on the Board.
Nine-month 2026 EPS was $1.72 and annualized ROAA was 1.30%, per the presentation.
CEO J. Bradley Scovill's retirement is planned for spring 2027; a CEO search is in progress.
Terry Lehman plans to step down as Chair in April 2027; Aaron Singer was appointed Vice Chair effective October 22, 2026.
Total assets were $3,150 million at September 30, 2026, with total deposits of $2,609 million.
Alpha Pro Tech reported third quarter 2026 net sales of $16.6 million, up 12.3% from $14.8 million a year earlier, and net income of $1.9 million, or $0.19 per diluted share, up from $976,000 or $0.09. The Disposable Protective Apparel segment drove most of the sales gain, and the company reported $25.5 million in cash and no debt as of September 30, 2026.
Disposable Protective Apparel segment sales rose 30.2% to $7.2 million; Building Supply segment sales rose 1.7% to $9.4 million.
Gross profit margin was 41.8% in the third quarter of 2026, compared with 39.7% a year earlier.
Net income was $1.9 million, or $0.19 per diluted share, compared with $976,000, or $0.09 per diluted share, in the third quarter of 2025.
As of September 30, 2026, cash was $25.5 million, working capital was $52.1 million, and the company had no debt.
Safe Pro Group announced a milestone U.S. Government prime contract award of $2.5 million from the U.S. Army. The contract, awarded under a Commercial Solutions Opening, covers its threat-detection software running on Anduril Industries' Ghost-X drone to protect Army Abrams tanks. The filing describes it as the company's first prime contract, but gives no revenue, profit, or timing figures for shareholders to judge its financial effect.
U.S. Army awarded Safe Pro a prime contract of $2.5 million under a Commercial Solutions Opening for Ground Threat Detection through Aerial Reconnaissance.
The software enables real-time identification and geolocation of more than 150 types of explosive threats, streamed into U.S. Army networks.
The Ghost-X platform has been selected by the U.S. Army under its Medium Range Reconnaissance program.
The release was dated November 10, 2026, and furnished as Exhibit 99.1 under Item 7.01.
Stabilis Solutions said it signed a three-year take-or-pay LNG supply agreement with an existing commercial aerospace customer at the John C. Stennis Space Center in Mississippi, covering January 1, 2027 through December 31, 2029. The filing gives contracted minimum volumes, which management says adds visibility into growth in 2027, though no revenue figure was disclosed.
Minimum commitment of 230,000 gallons per month and monthly volumes of up to 260,000 gallons
Take-or-pay term runs January 1, 2027 through December 31, 2029
Supply expected to come primarily from the owned Port Allen, Louisiana liquefaction facility
Stabilis has supplied LNG to this customer at Stennis since 2024
Veradermics reported results for the quarter ended September 30, 2026, with a net loss of $21.0 million, up from $20.1 million a year earlier, as general and administrative expenses rose to $12.7 million from $2.3 million. The company ended the quarter with $798.4 million in cash, cash equivalents and marketable securities, which it says should fund operations into 2030. For shareholders, the larger loss and higher overhead weigh against the positive clinical updates, and the filing reports no revenue for the quarter.
Q3 2026 net loss was $21.0 million, compared with $20.1 million in Q3 2025; nine-month net loss was $71.7 million versus $48.1 million.
G&A expenses rose to $12.7 million from $2.3 million, driven by payroll, stock-based compensation and commercial readiness costs.
R&D expenses fell to $16.1 million from $18.1 million; cash stood at $798.4 million on September 30, 2026, up from $141.9 million at December 31, 2025.
Topline data from Phase 2/3 Study '306' in female pattern hair loss is expected in the first half of 2027.
ACCESS Newswire reported third-quarter 2026 revenue of $5.5 million, down 4% from $5.7 million a year earlier, as press release volumes fell 12%. Net loss from continuing operations widened to $80,000, or $0.02 per diluted share, from $45,000 a year earlier, and Adjusted EBITDA fell to $829,000 from $933,000. The company said an October reorganization is expected to produce annualized savings of over $1.5 million, with the full benefit beginning in the first quarter of 2027.
Q3 2026 revenue was $5.5 million, down 4% from $5.7 million in Q3 2025 and down 2% from $5.6 million in Q2 2026.
Net loss from continuing operations was $80,000, or $0.02 per diluted share, versus $45,000, or $0.01 per share, a year earlier; operating loss narrowed to $142,000 from $184,000.
Gross margin was 75%, and cash flow from operations was $469,000 compared with a $582,000 outflow in Q3 2025.
Management expects annualized savings of over $1.5 million from October 2026 organizational changes and is focused on returning to top-line growth in 2027.
Virginia National Bankshares' Board declared an 8% stock dividend payable November 30, 2026, and a quarterly cash dividend of $0.38 per share, up $0.02 from the prior quarter, payable December 15, 2026. The company says the stock dividend takes effect first, so the cash dividend is paid on the larger share count, and shares outstanding will rise by about 430,000 to 5.9 million.
8% stock dividend: record date November 20, 2026, payable November 30, 2026; cash paid in lieu of fractional shares
Quarterly cash dividend of $0.38 per share, up $0.02, record date December 1, 2026, payable December 15, 2026
Shares outstanding to increase by about 430,000, from 5.4 million to 5.9 million
Cash dividend implies an annualized yield of approximately 2.85% based on the November 9, 2026 closing price
Terrestrial Energy reported a third-quarter 2026 net loss of $11.0 million, up from $9.3 million a year earlier, as research and development and stock-based compensation costs rose. Loss per share narrowed to $0.10 from $0.14 as the weighted-average share count increased to 105.9 million from 66.0 million. After quarter end, the company authorized a share repurchase program of up to $25 million funded with cash on hand.
Net loss of $11.0 million in the third quarter of 2026, compared with $9.3 million a year earlier and $9.4 million in the second quarter of 2026.
Basic and diluted loss per share of $0.10, compared with $0.14 in the third quarter of 2025.
Cash, cash equivalents and short-term investments of $276.3 million at September 30, 2026, versus $283.4 million at June 30, 2026, with no debt.
Authorized a share repurchase program of up to $25 million after quarter end.
Ocugen granted Celairis Therapeutics an exclusive, royalty-bearing license to commercialize its investigational gene therapy OCU400 for retinitis pigmentosa in eight named markets, including Australia, New Zealand, Singapore and Indonesia. Ocugen will receive up to $7.1 million in fees and milestone payments, plus a high-single-digit percentage royalty on net sales and 50% of gross profits, while retaining the sole right to manufacture the product in the territory.
Territory: Australia, Singapore, New Zealand, Malaysia, Thailand, Philippines, Vietnam and Indonesia, with possible expansion by mutual agreement
Up to $6.1 million, including an up-front fee and a fee payable on positive Phase 3 LiMeliGhT topline results; a $1.0 million milestone is payable on Australian Therapeutic Goods Administration approval
Ocugen receives a high-single-digit percentage royalty on net sales and 50% of gross profits; a supply agreement is targeted within 90 days
License runs until the latest of 20 years after first commercial sale, patent expiry, or regulatory exclusivity expiry
Flex filed slides from its Innovation Day in Austin, Texas, on November 10, 2026, covering its planned spin-off of Axiom Solutions International, which would hold its Cloud and Power Infrastructure segment. The materials set out the company's FY27 and FY29 directional targets, which matter to shareholders because they describe the planned mix and margin profile of both companies after the separation. The filing reports no new financial results.
Innovation Day held November 10, 2026, in person at Flex headquarters in Austin, Texas, with live webcasts for investors
Flex is targeting high-value markets at 35% to 40% of revenue by FY29, up from 24% in FY26, and adjusted operating margin of 7%+ (FY29 direction, not guidance)
Axiom would issue 200,000 shares of Series A Convertible Preferred Stock in a private placement led by GC Venture XIII (ASI), L.P.
Flex states the spin-off is on track to complete in calendar Q1 2027
PowerCompute reported preliminary, unaudited October 2026 Bitcoin mining results, with 9.0 Bitcoin mined, up from 7.5 a year earlier and 8.1 in September. Active hashrate rose 11.4% to approximately 800 PH/s by October 31, after the company installed about 900 more efficient miners on its existing 26 megawatts of power.
Bitcoin mined in October 2026 was 9.0, up 20% from 7.5 in October 2025 and up 11.1% from 8.1 in September 2026.
Active hashrate reached approximately 800 PH/s at October 31, 2026, up 11.4% from approximately 718 PH/s at September 30, 2026.
The company sold 7.0 Bitcoin in October 2026 and held 65.7 Bitcoin at October 31, valued at approximately $5.1 million at about $77,000 per Bitcoin.
Energy sales at the Oklahoma site generated approximately $46,000 in October 2026.
MaxCyte agreed to acquire Akron BioProducts for total consideration of $151.8 million, including $105.0 million in cash at closing, 20,639,733 new common shares, and $20.0 million in deferred cash payments, with closing expected before the end of 2026. The same day it reported third quarter revenue up 49% and a narrower net loss, and raised full-year 2026 revenue guidance to at least $34.5 million, but the deal adds share dilution, a new credit facility and reduced expected year-end cash.
Q3 2026 total revenue was $10.2 million, up 49% from $6.8 million; net loss narrowed to $4.8 million from $12.4 million
Full-year 2026 total revenue guidance raised to at least $34.5 million, excluding the Akron acquisition
Akron terms: $105.0 million cash at closing, 20,639,733 shares, and $20.0 million deferred in two $10.0 million payments in 2028 and 2029
Funding includes a MidCap Financial facility of up to $75.0 million; closing is subject to HSR review and Nasdaq listing approval
Dominari Holdings reported third-quarter 2026 revenue of $16.4 million, down about 69% from $52.4 million a year earlier, as underwriting, carried interest and commission revenue all fell. The company posted a net loss to common stockholders of $1.9 million, or $0.08 per share, compared with net income of $125.2 million, or $7.27 per diluted share, in the prior-year quarter, which was driven by a gain on its American Bitcoin Corp. investment; the loss narrowed from $5.4 million in the second quarter.
Q3 2026 total revenue was $16.4 million, versus $52.4 million in Q3 2025.
Q3 2026 net loss to common stockholders was $1.9 million, or $0.08 per share, versus net income of $125.2 million in Q3 2025.
Operating costs and expenses fell 65% to $18.3 million; nine-month operating loss narrowed to $40.6 million from $48.2 million.
Cash and cash equivalents were $24.0 million at September 30, 2026, and the company repurchased over 1.9 million shares for about $3.4 million under a $5.0 million program.
Worthington Enterprises furnished an investor presentation and a news release for its November 10, 2026 Investor and Analyst Day. The slides show trailing twelve-month net sales of $1.4 billion and free cash flow conversion of 116%, compared with the company's 85-90% target from its 2023 Investor Day.
Trailing twelve-month net sales of $1.4 billion as of fiscal 2027 Q1, up from $1.2 billion in fiscal 2024 per the slides
Free cash flow conversion of 116% for the fiscal 2027 Q1 trailing twelve months, versus an 85-90% target
Building Performance Solutions segment: $892 million net sales and $240 million adjusted EBITDA, a 27% adjusted EBITDA margin, on a trailing twelve-month basis
Long-term adjusted EBITDA margin target of 25%, per the presentation
KULR reported third-quarter 2026 revenue from continuing operations of $7.4 million, up 197% year over year, driven by product sales. Gross margin fell to 4% from 17%, and the operating loss widened to $11.0 million, so the reported net income of $4.5 million came from a $15.8 million non-recurring gain on digital assets rather than operations. The company also said it completed its exit from Bitcoin, has no debt, and ended the quarter with $54.5 million in cash.
Revenue was $7.40 million versus $2.49 million a year earlier; product sales were approximately $6.49 million, up 299%
Gross margin was 4% versus 17% a year earlier, which the company attributed to low-margin initial production builds and losses on several custom battery programs
Loss from operations was $11.00 million versus $8.74 million a year earlier; net income was $4.47 million, or $0.10 per share, including the $15.8 million non-recurring gain
A November 2026 reduction in force is expected to yield about $4 million in annualized savings, with severance costs of $0.35 million to $0.65 million
Atossa Therapeutics reported a third-quarter 2026 net loss of $5.6 million, or $0.56 per share, compared with $8.7 million, or $1.01 per share, a year earlier. Operating expenses fell to $5.9 million from $9.3 million, and the filing reports no revenue. Cash and cash equivalents were $20.6 million at September 30, 2026, down from $41.3 million at December 31, 2025, and the company also disclosed a contingent value rights agreement tied to a possible future priority review voucher sale.
Q3 2026 net loss was $5.6 million ($0.56 per share), versus $8.7 million ($1.01 per share) in Q3 2025.
Nine-month 2026 net loss was $23.7 million ($2.58 per share), versus $23.8 million ($2.76 per share) a year earlier.
Cash and cash equivalents were $20.6 million at September 30, 2026, versus $41.3 million at December 31, 2025.
Under the CVR agreement dated October 8, 2026, holders are entitled to 25% of net proceeds from the first qualifying FDA priority review voucher sale, capped at $50 million; no voucher has been awarded.
Cingulate's chairman and CEO discussed the company's work on the FDA's June 1, 2026 Complete Response Letter for CTx-1301 in a November 10, 2026 interview and press release. The company expects to resubmit the NDA between December 2026 and January 2027 and currently targets a commercial launch in the third quarter of 2027, subject to FDA approval, though the company states there is no assurance of resubmission timing, acceptance, or approval.
FDA issued a Complete Response Letter on June 1, 2026, requesting additional chemistry, manufacturing and controls (CMC) information and raising no concerns about clinical safety or efficacy.
Cingulate and its contract manufacturer have substantially completed the required CMC manufacturing work and expect to submit the NDA resubmission between December 2026 and January 2027.
A Class 1 resubmission carries a two-month review goal and a Class 2 resubmission a six-month goal; the company currently expects a commercial launch as early as the third quarter of 2027, subject to approval.
Corbus reported a third-quarter 2026 net loss of $37.8 million, up from $23.3 million a year earlier, driven by a $15.0 million development milestone under its CSPC license. Net loss per share narrowed to $1.81 from $1.90, but the filing shows a higher share count of 20,837,787 weighted shares. The company had $115.3 million in cash and investments and says it expects this to fund operations into 2028.
Net loss of $37.8 million, or $1.81 per share, for the quarter ended September 30, 2026, versus $23.3 million, or $1.90 per share, a year earlier
Operating expenses rose $14.4 million to $38.8 million, including a $15.0 million development milestone under the CSPC licensing agreement
Cash, cash equivalents and investments totaled $115.3 million at September 30, 2026, which the company expects to fund operations into 2028
TEMPO-1 Phase 3 study of sutantatug envedotin began dosing in September 2026; CANYON-1 Phase 1b topline data for CRB-913 will be presented at ObesityWeek on November 15, 2026
TriSalus Life Sciences reported third-quarter 2026 revenue of $12.9 million, up 11.3% from a year earlier, and narrowed its operating loss to $7.7 million from $9.0 million. The company revised its full-year 2026 revenue guidance to $46 million to $48 million, which it said represents growth of about 2% to 6% over 2025, and said team productivity has ramped slightly slower than anticipated.
Q3 2026 revenue $12.9 million, up 11.3% year over year; gross margin 86.2% vs. 83.5%
Net loss attributable to common stockholders $8.9 million, or $0.15 per share, vs. $41.3 million, or $0.96 per share, in Q3 2025; prior-year figure included about $30.5 million tied to a preferred stock conversion
Full-year 2026 revenue guidance revised to $46 million to $48 million
Cash and cash equivalents $41.1 million at September 30, 2026
Coursera committed on November 9, 2026 to a workforce reduction plan tied to its May 2026 combination with Udemy, aiming to align costs and operations after the merger. The company expects to terminate about 10% of its global workforce and to incur $14 million to $17 million in charges, mostly severance and healthcare benefits, largely paid in cash during the fourth quarter of 2026 and the first half of 2027.
Plan to terminate approximately 10% of Coursera's global workforce
Estimated expenses of $14 million to $17 million, mainly termination benefits including severance and healthcare
Charges expected mostly in cash during Q4 2026 and first half of 2027; local law and consultation may extend timing
Company says it will disclose costs of broader merger synergy initiatives in future periodic reports
PDS Biotechnology said NantWorks exercised outstanding common stock warrants at $0.22 per share, for 17,699,115 shares or pre-funded warrants in lieu of shares, bringing about $3.9 million in gross proceeds to the company. The warrants came from a September 2026 private placement that raised about $11.3 million gross, and the company plans to use the proceeds to support its lead program and general corporate purposes.
NantWorks exercised warrants for 17,699,115 shares at $0.22 per share, about $3.9 million in gross proceeds.
Warrants were issued in the private placement that initially closed on September 14, 2026, which raised about $11.3 million gross.
Exercise above the 19.9% beneficial ownership limit was taken as pre-funded warrants at $0.00033 per share, which do not expire.
Proceeds, with September 2026 placement net proceeds, will support PDS0301 toward a Phase 3 trial in metastatic colorectal cancer, the PDS0101 partnership strategy and general corporate purposes.
Jerash Holdings (US), Inc. reported fiscal 2027 second-quarter results for the quarter ended September 30, 2026, with revenue up 19.8% and net income of $2.2 million, or $0.16 per diluted share, versus $479,000 a year earlier. The company also guided to fiscal third-quarter revenue of approximately $49 million to $51 million and a gross margin of approximately 16% to 17%.
Q2 revenue rose 19.8% to $50.3 million from $42.0 million; gross margin rose 320 basis points to 18.2%
Operating income was $3.1 million, up from $1.1 million; net income was $2.2 million, or $0.16 per diluted share
Q3 outlook: revenue of approximately $49 million to $51 million and gross margin of approximately 16% to 17%
Board approved a regular quarterly dividend of $0.05 per share on November 5, 2026, payable November 23, 2026 to holders of record as of November 16, 2026
Aviat Networks reported fiscal 2027 first-quarter revenue of $102.0 million, down 5.0% from $107.3 million a year earlier, and a GAAP net loss of $2.8 million, or $0.22 per diluted share, versus net income of $0.2 million a year earlier. The company also updated its full-year fiscal 2027 guidance to revenue of $450 million to $475 million and Adjusted EBITDA of $50.0 million to $55.0 million, but the filing does not give prior guidance figures for comparison.
Q1 revenue $102.0 million vs. $107.3 million a year earlier; GAAP gross margin fell to 29.6% from 33.2%
GAAP net loss of $2.8 million ($0.22 per diluted share) vs. net income of $0.2 million; non-GAAP net income of $1.5 million ($0.12 per share) vs. $5.5 million ($0.43)
Bookings of over $150 million, up 75% year over year; Adjusted EBITDA of $6.0 million vs. $9.1 million
Cash of $55.4 million at October 2, 2026, down from $72.8 million at July 3, 2026; total debt of $85.9 million
Tyra Biosciences reported third quarter 2026 results with a net loss of $51.1 million, up from $29.9 million a year earlier, as research and development and general and administrative expenses rose. The company said it ended the quarter with $700.5 million in cash, cash equivalents and marketable securities, and that this, together with a $400 million financing completed in September 2026, funds planned operations through 2030.
Net loss was $51.1 million, or $0.74 per share, for the quarter ended September 30, 2026, compared with $29.9 million, or $0.50 per share, a year earlier.
R&D expenses rose to $43.1 million from $25.5 million, driven mainly by dabogratinib trials; G&A expenses rose to $11.7 million from $7.5 million.
Initial Phase 2 SURF302 results reported in September 2026 showed a 79% overall response rate at 60 mg QD among 14 participants with single and multiple marker lesions.
Cash, cash equivalents and marketable securities were $700.5 million as of September 30, 2026.
Coya Therapeutics reported a third-quarter 2026 net loss of $10.6 million, up from $2.1 million a year earlier, as collaboration revenue fell to $0.2 million from $3.6 million and research and development expenses rose to $8.6 million. The company said enrollment is complete in its Phase 2/3 ALSTARS trial of COYA 302 for ALS, with topline data expected in early Q2 2027, and that its $35.8 million in cash is sufficient into the second half of 2027.
Net loss of $10.6 million for the quarter ended September 30, 2026, versus $2.1 million a year earlier
Collaboration revenue of $0.2 million, down from $3.6 million in the prior-year quarter, which included a $3.3 million license recognition
Research and development expenses rose to $8.6 million from $2.9 million, mainly due to the COYA 302 ALS Phase 2/3 trial
Cash and cash equivalents of $35.8 million as of September 30, 2026; topline ALSTARS data expected early Q2 2027
Co-Diagnostics reported third quarter 2026 revenue of $0.3 million, up from $0.1 million a year earlier, and operating expenses fell 12% to $6.2 million. The net loss widened to $6.3 million from $5.9 million, mainly because the prior-year period included an income tax benefit, and cash was $0.7 million at September 30, 2026. Shortly after quarter end, the company completed a senior secured convertible debt financing with about $2.1 million in initial funding, which shareholders should weigh against the company's limited cash.
Q3 2026 revenue was $282,881 versus $145,380 in Q3 2025; cost of revenue of $303,344 exceeded revenue, producing a gross loss of $20,463
Operating loss narrowed to $6.3 million from $7.0 million; net loss was $6.3 million, or $1.01 per share, versus $5.9 million, or $4.66 per share, a year earlier
Cash and cash equivalents totaled $0.7 million at September 30, 2026, compared with $11.9 million at December 31, 2025
After quarter end, a senior secured convertible debt financing with J.J. Astor & Co. provided about $2.1 million in initial funding, with up to $1.0 million more subject to conditions
Aptera Motors notified Cantor Fitzgerald on November 9, 2026 that it is suspending and terminating the prospectus for its at-the-market share sale program, so it will make no sales under that program unless a new prospectus is filed. The company also gave preliminary, unaudited cash of about $9.2 million at September 30, 2026, including about $4.1 million of refundable customer reservation fees, for the quarter whose financial statements are not yet final.
Company delivered notice to Cantor Fitzgerald on November 9, 2026 suspending and terminating the ATM prospectus dated October 9, 2026.
Sales Agreement dated October 1, 2026 otherwise remains in full force and effect.
Preliminary cash and cash equivalents of about $9.2 million at September 30, 2026, including about $4.1 million of refundable customer reservation fees.
Preliminary figures are unaudited and subject to final closing procedures; the auditor has not reviewed them.
America's Car-Mart amended its credit agreement with Silver Point Finance and lenders to waive certain anticipated or existing events of default through September 7, 2026, and has since extended that date and related relief repeatedly. On November 9, 2026, the agent and lenders agreed to extend the Scheduled Termination Date and temporary relief on minimum liquidity and Collateral Coverage Ratio requirements through November 12, 2026, which signals the company is operating under short-term lender forbearance.
Credit Agreement dated October 30, 2025, amended by First Amendment and Limited Waiver with Silver Point Finance, LLC as Agent
Scheduled Termination Date extended from September 7, 2026 to November 9, 2026 and then to November 12, 2026
Temporary relief on minimum liquidity thresholds and minimum Collateral Coverage Ratio extended through November 12, 2026
PepGen reported positive topline results from the 10 mg/kg cohort of its Phase 2 FREEDOM2-DM1 trial in myotonic dystrophy type 1, with mean splicing correction of 46.5% and no serious or severe adverse events reported. For the quarter ended September 30, 2026, the net loss widened to $19.4 million from $18.0 million a year earlier, and cash, cash equivalents and marketable securities were $104.8 million, which the company says will fund operations into 2028. The loss per share narrowed to $(0.28) from $(0.52), but weighted-average shares rose to 69,260,353 from 34,362,876, and the FDA's partial clinical hold on the FREEDOM2 study remains in place.
10 mg/kg cohort: mean splicing correction of 46.5% at Week 13; five of six participants above 20% and four above 50%
Net loss of $19.4 million for the quarter versus $18.0 million a year earlier; research and development expenses were $14.5 million versus $13.4 million
Cash, cash equivalents and marketable securities were $104.8 million at September 30, 2026, down from $148.5 million at December 31, 2025
12.5 mg/kg cohort is fully enrolled with results expected in the first half of 2027; FREEDOM-OLE 10 mg/kg safety and 5 mg/kg clinical data expected in January 2027
AST SpaceMobile and Rakuten Group agreed to establish Rakuten AST, Inc., a joint venture to build a direct-to-device satellite network in Japan. The joint venture is expected to receive up to 148 billion yen (about $1 billion) in Japanese government support over roughly three years, and AST SpaceMobile will supply the satellites. The filing contains no revenue, profit, or financial impact figures for AST SpaceMobile itself.
Rakuten AST, Inc. agreed to be established November 6, 2026; planned establishment in November 2026
Rakuten Group holds 51% and AST SpaceMobile's Japanese subsidiary holds 49%
Expected up to 148 billion yen (about $1 billion) in support over about three years under Japan's J-LEO project
Planned commencement of domestic operations by the end of March 2029
PMV Pharmaceuticals reported third-quarter 2026 results, with a net loss of $34.4 million, or $0.52 per share, compared with $21.1 million, or $0.40 per share, a year earlier. The increase was mainly a $12.8 million non-cash warrant liability charge tied to the August 2026 public offering, while operating expenses fell, and the company said its cash runway extends into the first quarter of 2028.
Net loss was $34.4 million for the quarter ended September 30, 2026, versus $21.1 million a year earlier; the increase was primarily a $12.8 million non-cash loss from the change in fair value of the warrant liability.
R&D expenses fell to $16.1 million from $18.2 million, and G&A expenses fell to $4.0 million from $4.3 million.
Cash, cash equivalents, and marketable securities were $108.5 million as of September 30, 2026, which the company said supports a cash runway into the first quarter of 2028.
The company plans to submit a New Drug Application for rezatapopt in platinum-resistant/refractory ovarian cancer in the first quarter of 2027.
Alliance Laundry reported third-quarter 2026 net revenues of $461 million, up 5% from a year earlier, and net income of $65 million compared with $33 million. It raised its full-year 2026 Adjusted EBITDA growth guidance to about 10%, the high end of its prior 8% to 10% range, while keeping revenue growth guidance at 6% to 7%. The company also repurchased $75 million of its common stock during the quarter.
Net revenues were $461 million, up 5% from $438 million; North America revenue rose 8% to $356 million.
Net income was $65 million versus $33 million; diluted EPS was $0.32 versus $0.19.
Adjusted EBITDA rose 14% to $127 million, with a 27.5% margin; a discrete tariff refund benefit helped results.
The company repurchased $75 million of stock and repaid $45 million of debt, reducing net leverage to 2.25x.
HIVE reported revenue of $84.9 million for the quarter ended September 30, 2026, up 7.3% from the prior quarter but down 2.7% from a year earlier. The GAAP net loss widened to $78.7 million from $15.8 million a year earlier, including a $31.2 million non-cash impairment of mining equipment. Shareholders face a mix of sequential improvement, a year-over-year revenue decline and a larger loss.
Revenue $84.9 million, up 7.3% sequentially and down 2.7% year over year; HPC revenue $8.8 million, up 70.7% year over year
GAAP net loss $78.7 million, or $0.29 per share, versus a net loss of $15.8 million in the year-earlier quarter
Non-cash charges included $54.9 million of depreciation and a $31.2 million impairment of mining equipment
Cash and cash equivalents $139.0 million as of September 30, 2026; HIVE targets about $200 million of GPU Cloud ARR by Q4 calendar 2026
Kalaris Therapeutics reported a third-quarter net loss of $11.0 million, down from $11.9 million a year earlier, and $82.9 million in cash and marketable securities as of September 30, 2026. The company said a pilot manufacturer batch failed a release specification, pushing preliminary Phase 1b/2 data for TH103 in neovascular AMD to 2H 2027 and extending its cash runway into 2028.
Net loss was $11.0 million for the quarter ended September 30, 2026, versus $11.9 million a year earlier; net loss per share was $0.46 versus $0.64.
Research and development expenses were $8.3 million, down from $9.1 million; general and administrative expenses were $3.5 million, down from $3.6 million.
Cash, cash equivalents and marketable securities were $82.9 million, down from $118.0 million at December 31, 2025, and are expected to fund operations into 2028.
A new TH103 batch is now expected in Q2 2027, and technology transfer to KBI Biopharma was completed with test batches meeting target specifications.
Mirum Pharmaceuticals announced that brelovitug met the primary endpoint at Week 24 in the Phase 3 AZURE-4 study for chronic hepatitis delta virus. AZURE-4 is the second of two Phase 3 studies forming the basis of the company's planned U.S. registration package, and the company plans to submit a Biologics License Application to the FDA in the first half of 2027.
At Week 24, 59% of patients on 300 mg weekly and 44% on 900 mg every four weeks met the combined virologic response and ALT normalization endpoint, versus 0% in the delayed-treatment arm (p≤0.0001).
The study enrolled 113 treatment-naïve patients, 53% of whom had cirrhosis.
Flu-like illness was the most common adverse event, reported in 17.2% (300 mg weekly) and 18.5% (900 mg every four weeks) of participants.
A potential U.S. commercial launch is expected in the fourth quarter of 2027, if approved.
MasterCraft reported results for the first three months of its transition period ended October 4, 2026, following its May 15, 2026 merger with Marine Products and a change in fiscal year-end to December 31. Net sales, income from continuing operations, and Adjusted EBITDA all rose from the prior-year period, though gross margin fell 120 basis points, largely due to the Marine Products business. The company also gave outlook for the six-month transition period ending December 31, 2026.
Net sales were $154.1 million, up $85.1 million or 123.4%; excluding the Marine Products contribution, sales rose 37.4%, or $25.8 million.
Income from continuing operations was $12.1 million, or $0.50 per diluted share, versus $3.7 million, or $0.22, a year earlier.
Adjusted EBITDA was $20.1 million, a 13.0% margin, compared with $7.0 million and 10.1% in the prior-year period.
For the transition period, the company expects net sales of $293 million to $297 million, Adjusted EBITDA of $32 million to $34 million, and Adjusted EPS of $0.75 to $0.80.
Xilio Therapeutics reported third quarter 2026 results for the period ended September 30, 2026. Collaboration and license revenue fell to $10.0 million from $19.1 million a year earlier, while the net loss narrowed to $5.9 million from $16.3 million, mainly because of a non-cash warrant fair value gain, and operating loss widened. The company says its cash will fund operations into the first quarter of 2028, excluding up to $36.2 million in possible Series C warrant proceeds.
Collaboration and license revenue was $10.0 million, down from $19.1 million in Q3 2025, driven by lower revenue under the AbbVie and Gilead agreements.
Net loss was $5.9 million, or $(0.30) per share, versus $16.3 million, or $(1.58) per share, a year earlier; the change in fair value of warrant liabilities was a $4.8 million gain versus a $15.4 million loss.
Loss from operations was $11.7 million versus $1.9 million a year earlier, as R&D expenses rose to $14.8 million and G&A expenses to $6.9 million.
Cash and cash equivalents were $122.2 million at September 30, 2026, with runway stated into the first quarter of 2028.
On November 5, 2026, Codexis and its subsidiary entered a Loan and Security Agreement with Trinity Capital Inc. as agent, providing up to $60.0 million in term loans, of which $42.5 million was funded at closing. The company used that loan and cash on hand to repay its Innovatus loan in full, and issued lender warrants for up to 1,666,668 shares of common stock, which would increase the share count if exercised.
Tranche A term loan of $42.5 million funded November 5, 2026; up to $60.0 million available in total across three tranches
Interest at the greater of 10.50% or a variable rate tied to prime plus 3.75%; interest-only until November 1, 2030; maturity November 1, 2031
Repaid the Innovatus Loan Agreement in full for an aggregate of approximately $43.6 million
Lender warrants for up to 1,666,668 shares at $1.08 per share, expiring November 5, 2036; loans secured by substantially all assets
Exagen reported third-quarter 2026 revenue of $18.4 million, up 7% from $17.2 million a year earlier, and a net loss of $6.3 million, compared with $7.1 million in the prior-year quarter. The company reiterated its full-year 2026 revenue guidance of $72 million to $75 million, which means results did not change its outlook.
Q3 2026 revenue $18.4 million vs. $17.2 million in Q3 2025; nine-month revenue $55.7 million, up 11%
Q3 2026 net loss $6.3 million vs. $7.1 million; nine-month net loss $13.5 million vs. $15.3 million
Full-year 2026 revenue guidance of $72 million to $75 million reiterated; cash and equivalents $28.1 million at September 30, 2026
LCI Industries said its board unanimously determined that a revised, unsolicited, non-binding proposal from Monomoy Capital Partners at $104.50 per share in cash is not a superior proposal and is not reasonably likely to lead to one. The board continues to recommend the pending merger with Patrick Industries, and shareholders will vote on it at a Special Meeting on November 18, 2026, which matters because a vote against the Patrick merger is not a vote for the Monomoy proposal.
Monomoy's revised proposal is $104.50 per share in cash, described by the board as a modest increase over its initial offer
Special Meeting of Shareholders scheduled for November 18, 2026
ISS and Glass Lewis both recommended that LCI shareholders vote FOR the Patrick merger
The companies remain on track to complete the transaction in the first half of 2027, subject to shareholder and regulatory approvals
Ambiq Micro reported third-quarter 2026 net sales of $38.1 million, up 110% from a year earlier, and a GAAP net loss of $7.1 million, narrowed from $9.0 million in the third quarter of 2025. The company expects fourth-quarter 2026 net sales of $43.5 million to $44.5 million, above the third-quarter level, and cited accelerating edge AI demand. Shareholders are seeing faster sales growth and a smaller loss, though the company used $25.4 million in operating cash over the first nine months of 2026.
Q3 2026 net sales were $38.1 million, up from $18.2 million in Q3 2025; GAAP gross margin was 46.7%.
GAAP net loss was $7.1 million in Q3 2026, compared with $9.0 million a year earlier.
Q4 2026 guidance: net sales of $43.5 million to $44.5 million and non-GAAP net loss per share of ($0.09) to ($0.03).
Cash and cash equivalents were $363.5 million at September 30, 2026, up from $140.3 million at December 31, 2025.
At its Capital Markets Day on November 9, 2026, Entegris presented long-term targets of about 15% revenue CAGR, about 55% adjusted gross margin, about 35% adjusted operating margin and about 30% adjusted EPS CAGR. The Board authorized a share repurchase program of up to $500 million with no expiration date, and the company expects to raise its quarterly cash dividend by 10% beginning in the first quarter of 2027, subject to Board approval. The targets are long-term and not current results, but the buyback and dividend plan are concrete capital return steps for shareholders.
Board authorized repurchases of up to $500 million of common stock on November 8, 2026, with no expiration date.
Quarterly cash dividend expected to rise 10% beginning in the first quarter of 2027, subject to Board declaration.
Long-term targets: revenue CAGR of about 15%, adjusted gross margin of about 55%, adjusted operating margin of about 35%, adjusted EPS CAGR of about 30%.
Management says it expects to return about 50% of excess cash to shareholders.
Arbutus reported third-quarter 2026 net income of $59.1 million, driven mainly by a $67.3 million dividend from Genevant, compared with a net loss of $7.7 million a year earlier. Revenue fell to $0.3 million from $0.5 million, and the operating loss widened to $10.5 million from $8.7 million. The company ended the quarter with $337.5 million in cash and investments after returning $230 million to shareholders through a tender offer in early October.
Net income was $59.1 million, or $0.30 per basic and diluted share, for the quarter ended September 30, 2026, versus a net loss of $0.04 per share a year earlier.
Total revenue was $0.3 million, down from $0.5 million, and the operating loss was $10.5 million, compared with $8.7 million.
A $230 million Dutch Auction tender offer completed in early October 2026 bought 46 million shares at $5.00 per share, about 23% of shares outstanding as of September 29, 2026.
The FDA lifted the clinical hold on the AB-101 IND application in October 2026.
Kustom Entertainment reported third-quarter 2026 revenue from continuing operations up 57% to $2.7 million, but a loss from continuing operations of $2,670,888 widened from $994,761 a year earlier. Net income of $2,346,315 was driven by a $5,017,203 gain from discontinued operations tied to the sale of its legacy video solutions business to Cycurion, Inc. For shareholders, the results show revenue growth alongside a larger operating loss, and the pending $TFL acquisition's closing depends on financing and an extended outside date of December 18, 2026.
Service revenue grew 65% to $2.1 million, driven mainly by transaction volume on the TicketSmarter marketplace.
Loss from continuing operations was $2,670,888, or $(5.13) per share, versus $(994,761), or $(86.38) per share, a year earlier; about $625,000 of the increase was non-cash expense.
Net income attributable to common stockholders was $2,346,315, or $4.51 per basic and diluted share, after $5,017,203 of income from discontinued operations.
Stockholders approved the TFL, LLC acquisition on October 5, 2026; the purchase agreement's outside date was extended to December 18, 2026.
Energy Focus reported third quarter 2026 net sales of $4.8 million, up from $0.8 million a year earlier, and net income of $0.5 million, or $0.08 per share, compared with a net loss of $0.2 million in the third quarter of 2025. The company attributed the growth mainly to a Taiwan Uninterruptible Power Supply project with a new customer, and its forward-looking statements still cite substantial doubt about its ability to continue as a going concern.
Q3 2026 net sales were $4.8 million, up 481.2% year over year and up 28.1% from $3.7 million in Q2 2026.
Q3 2026 net income was $0.5 million, or $0.08 per diluted share, versus a Q2 2026 net loss of $0.9 million, or $(0.14) per share.
Nine-month 2026 net loss was $0.5 million, or $(0.08) per share, compared with $0.7 million, or $(0.12) per share, in the same period of 2025.
Cash was $3.3 million at September 30, 2026, including $0.9 million of short-term borrowings proceeds, versus $1.1 million at December 31, 2025.
Cellectar Biosciences reported a third-quarter 2026 net loss of $8.0 million, or $0.46 per share, up from $4.4 million, or $1.41 per share, a year earlier. Research and development expenses rose to $5.4 million from $2.5 million, tied to the start of its Phase 3 confirmatory trial and its CLR 125 Phase 1b trial. The company said its September 30, 2026 cash balance is adequate to fund budgeted operations into the second quarter of 2027.
Q3 2026 net loss was $8.0 million, or $0.46 per share, versus $4.4 million, or $1.41 per share, in Q3 2025.
R&D expenses were about $5.4 million versus about $2.5 million a year earlier; G&A expenses were about $2.7 million versus $2.3 million.
Cash and cash equivalents were $24.6 million at September 30, 2026, including net proceeds of about $31.7 million from a May 2026 offering.
The company plans to dose the first patient in its Phase 3 confirmatory trial in Q1 2027 and submit an NDA seeking accelerated approval in 1H 2027.
Autolus reported third-quarter 2026 AUCATZYL net product revenue of $41.2 million, up from $21.1 million a year earlier, and now expects full-year 2026 AUCATZYL net product revenue at or above the upper end of $150 million, up from prior guidance. The company also reported a narrower net loss and said its cash is expected to fund operations into Q2 2028.
Q3 2026 net product revenue was $41.2 million versus $21.1 million in Q3 2025.
Gross margin was 57%, up from 55% in Q2 2026 and negative in Q3 2025.
Net loss was $55.1 million, compared with $79.1 million in the year-earlier quarter; loss per share was $(0.21) versus $(0.30).
Cash, cash equivalents and marketable securities were $248.4 million at September 30, 2026, up from $201.6 million at June 30, 2026, mainly from Perceptive senior secured note inflows.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.